PRNewsWire
28 May 2026, 08:21 UTC · 2h ago
Source · https://www.prnewswire.com/news-releases/aphranel-magiccrystal-caha-filler-achieves-eu-mdr-certification-as-a-premium-regenerative-injectable-302784208.html
Read source
Search tags
Story key points
3 claims · impact-rated
Moyom Biotechnology's Aphranel® MagiCCrystal CaHA Filler has officially achieved European Union Medical Device Regulation (EU MDR) certification. — EU MDR certification is a high regulatory hurdle that opens the entire European market for this high-end medical product, directly enabling international revenue growth.
+0.60Aphranel is among the first regenerative CaHA injectable fillers from the Asia-Pacific region to be certified under the EU MDR framework. — This establishes a competitive first-mover advantage for a Chinese-origin brand in a sector historically dominated by a few international players.
+0.30The product is positioned as a high-end offering in China with a recommended retail price of RMB 12,800 per 0.5 mL syringe. — High price positioning indicates strong profit margins and a target luxury consumer segment.
+0.20Ticker attribution
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
